Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Artneo
- Development stage
- Unknown
- Lead developer
- Petrovax Pharm
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Recombinant Proteins and Enzymes, Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules
- Administration
- Oral
01
Overview
Artneo is a multi-ingredient nutraceutical combination product designed for joint health and the management of osteoarthritis symptoms. It contains undenatured (native) type II collagen, which acts via oral tolerance to modulate the immune response against joint cartilage; methylsulfonylmethane (MSM), a source of organic sulfur for connective tissue; *Boswellia serrata* extract (rich in boswellic acids) for anti-inflammatory effects; and vitamins C and D3 to support collagen synthesis and bone health. Clinical data published in 2023 suggests that Artneo demonstrates non-inferiority to traditional chondroprotectors, such as the combination of glucosamine and chondroitin, in reducing pain and improving function in patients with stage I-III knee osteoarthritis.
- Brand names
- Artneo
- Other names
- undenatured collagen type II + methylsulfonylmethane + boswellia serrata + vitamin D3 + vitamin C
02
Targets
VDR (Vitamin D receptor)ALOX5 (Arachidonate 5-lipoxygenase)
Beyond the preview
Go deeper on Artneo.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Artneo.